Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR
摘要:
With the use of an NMR-based method, potent (IC50 < 25 nM) nonpeptide inhibitors of the matrix metalloproteinase stromelysin (MMP-3) were discovered. The method, called SAR by NMR (for structure-activity relationships by nuclear magnetic resonance), involves the identification, optimization, and linking of compounds that bind to proximal sites on a protein. Using this technique, two ligands that bind weakly to stromelysin (acetohydroxamic acid, K-D = 17 mM; 3-(cyanomethyl)-4'-hydroxybiphenyl, K-D = 0.02 mM) were identified. On the basis of NMR-derived structural information, the two fragments were connected to produce a 15 nM inhibitor of this enzyme. This compound was rapidly discovered (less than 6 months) and required only a minimal amount of chemical synthesis. These studies indicate that the SAR by NMR method can be effectively applied to enzymes to yield potent lead inhibitors-an important part of the drug discovery process.
Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR
摘要:
With the use of an NMR-based method, potent (IC50 < 25 nM) nonpeptide inhibitors of the matrix metalloproteinase stromelysin (MMP-3) were discovered. The method, called SAR by NMR (for structure-activity relationships by nuclear magnetic resonance), involves the identification, optimization, and linking of compounds that bind to proximal sites on a protein. Using this technique, two ligands that bind weakly to stromelysin (acetohydroxamic acid, K-D = 17 mM; 3-(cyanomethyl)-4'-hydroxybiphenyl, K-D = 0.02 mM) were identified. On the basis of NMR-derived structural information, the two fragments were connected to produce a 15 nM inhibitor of this enzyme. This compound was rapidly discovered (less than 6 months) and required only a minimal amount of chemical synthesis. These studies indicate that the SAR by NMR method can be effectively applied to enzymes to yield potent lead inhibitors-an important part of the drug discovery process.
[EN] HYDROXAMID ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS<br/>[FR] DERIVES D'ACIDE HYDROXAMIQUE UTILISES COMME INHIBITEURS DE L'HISTONE DESACETYLASE (HDAC)
申请人:FUJISAWA PHARMACEUTICAL CO
公开号:WO2004063169A1
公开(公告)日:2004-07-29
A compound having the following formula (I): wherein R1 is N-containing heterocyclic ring optionally substituted with one or more suitable substituent(s), R2 is hydroxyamino, R3 is hydrogen or a suitable substituent, L1 is -(CH?2#191)?n#191- (wherein n is an integer of 0 to 6) optionally substituted with one or more suitable substituent(s), wherein one or more methylene(s) may be replaced with suitable heteroatom(s), and L2 is lower alkenylene, or a salt thereof. The compound is useful as a histone deacetylase inhibitor.
Biphenyl hydroxamate inhibitors of matrix metalloproteinases
申请人:Abbott Laboratories
公开号:US05665777A1
公开(公告)日:1997-09-09
Compounds of formula ##STR1## or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF.alpha. secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF.alpha. secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF.alpha. secretion.
BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES
申请人:Abbott Laboratories
公开号:EP0874808A1
公开(公告)日:1998-11-04
US5665777A
申请人:——
公开号:US5665777A
公开(公告)日:1997-09-09
[EN] BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES<br/>[FR] INHIBITEURS DE METALLOPROTEINASES MATRICIELLES, A L'HYDROXAMATE BIPHENYLIQUE
申请人:ABBOTT LABORATORIES
公开号:WO1997018188A1
公开(公告)日:1997-05-22
(EN) Compounds of formula (I), or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF$g(a) secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF$g(a) secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF$g(a) secretion.(FR) L'invention concerne des composés de formule (I) ou un sel pharmaceutiquement acceptable de ceux-ci, qui inhibent la sécrétion des métalloprotéinases matricielles et de TNF$g(a) et sont utiles dans le traitement de pathologies inflammatoires. Elle porte aussi sur des compositions inhibant la sécrétion de métalloprotéinases matricielles et de TNF$g(a) et sur une méthode d'inhibition de la sécrétion de métalloprotéinases matricielles et de TNF$g(a).